The new EU Plant Protection Products Regulation

Isabelle Rety-Guitton, EU Regulatory Manager, SynTech Research France
2011 sees implementation of the new legislation for the Plant Protection Products (PPP) (Authorization) – Regulation (EC1107/2009) – which will apply from 14 June.  Some clarity on the resulting new procedures is beginning to emerge, including aspects of the new Zonal System and Efficacy Data requirements for formulated products (Section 7),  In summary, the key points of this Section are:

  • National aspects are to be kept to a minimum:  The aim is to include as much information in core/zonal dossiers, rather than as national addenda: there will be recognition of data according to EPPO zones across regions and acceptance of data from other regions/sources, as long as relevant scientific justification is provided in the data package. If a Zonal Rapporteur Member State (ZRMS) has to evaluate efficacy for uses outside their normal area of expertise specialists in other Member States can be called on for advice.
  • Official methods and standards: Data generated according to EPPO guidelines will be accepted, so the ZRMS should only need to determine compliance of the studies with EPPO standards.  Specific country test methods, e.g. the French CEB, will only apply to trials conducted in that Member State -such as the inclusion of specific commercial standards.
  • Numbers of trials: In theory, a maximum three Biological Assessment Dossiers (BADs) are needed (one per zone) for a formulated product, as it will not be necessary for applicants to submit any National BADs.  The guidance documents which will arise from the continuing work on harmonization of data requirements will probably provide us with more information of the needs – but not necessarily precise number of trials needed to address the different situations.

But we believe that the option for Member States to require National Addenda, and the continued need for territorial data for country technical support and marketing, will still mean that high quality efficacy trials will still be needed in all EU territories where it is intended to market the product.

Other related posts

SynTech Research Group Releases 2024 CSR Report

At SynTech Research Group, our commitment to sustainability, ethical practices, and social responsibility is central to everything we do. Today, we are proud to announce the release of our 2024 Environmental, Social, and Governance (ESG)... read more

Good Place to Work – Interviewing Karine Faye

We are excited to feature Karine Faye, an indispensable member of SynTech Research Group, based in La Chapelle de Guinchay, France. In this interview, Karine shares her insights into her role, motivations and experiences working... read more

Good Place to Work – Exchange Programme Interview

We are excited to feature an interview with Cyrielle Desprez, Field Technician, on her exchange in Reedley, California. The SynTech Talent Exchange programme provides the opportunity for our staff to go and experience being part... read more

Good Place to Work – Interviewing AgIdea’s colleagues

In this edition, we’re excited to introduce you to three colleagues from AgIdea, oe of the latest additions to the SynTech Research Group family as of early 2025. With AgIdea integrated into our global network,... read more

SynTech Research Group Integrates GLP Estrategias Avanzadas in its expansion in the Americas

SynTech Research Group, leading Agricultural Contract Research Organization (CRO), is pleased to announce the integration of GLP Estrategias Avanzadas to the group, a prominent player in agricultural, chemical, and life sciences regulatory and strategic consultancy... read more

Interviewing our New Hires – Their first impressions working at SynTech Research Group

To foster better connections and learn about the experiences of our new colleagues during their initial months at SynTech Research Group, we interviewed three team members about their first impressions of the company. Meet our... read more